Axoltis Pharma

Éric Cohen - Managing Director and Founder of Agile Capital Markets

About the deal

Clermont-Ferrand, France, December 2, 2025 – Axoltis Pharma, a biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announces the closing of a Series A funding round worth €18 million ($20.9M), to be disbursed in two installments.

The funding, which includes new and historic investors, will enable the company to pursue the development of NX210c, its lead drug candidate, currently in phase 2 clinical trials in patients with ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig’s disease.

Press release

Date 2025

Sector Biotech

Transaction Size €18M

Transaction Type Series A

Localisation France